

Ripudaman Singh is the Chief Technology Officer at ARCEDI Biotech ApS, a Danish biotech company that has developed a technology for non-invasive prenatal diagnosis (cbNIPD) on rare fetal cells isolated from maternal blood. Ripudaman has 10 years of experience in developing technologies for the enrichment and detection of fetal cells. His team was the first to publish the expression profile data on circulating fetal cells showing that these cells have a placental origin. Ripudaman has a PhD in Medicine (Genetics of Human Longevity) from Aarhus University, Denmark, and MBA from Aarhus School of Business.